Sapphire Ventures ads

Europe has one of the world’s largest economies, yet only a fraction of consumers invest. Upvest is aiming to close that gap, making investing as easy as spending money. Upvest powers a new generation of investing platforms with a modern, scalable Investment API, built to replace legacy infrastructure and expand access to capital markets. In December 2024, Sapphire Ventures was thrilled to formally partner with Upvest through its Series C, supporting the company in its latest funding round and into its next chapter. Sapphire Ventures Partner Andreas Weiskam recently caught up with Founder and CEO Martin Kassing to discuss: 🔹 What it takes to build mission-critical financial infrastructure in a highly regulated market 🔹 How Upvest scaled into a truly pan-European platform while adapting to local complexity 🔹 Why product-first thinking matters when competing with deeply entrenched incumbents 🔹 How AI could reshape both the back office and the future of financial advice Check out their full conversation below. ⬇️ 🎬

Our 2026 AI outlook: 10 predictions on enterprise, infrastructure, and the forces reshaping the market.

We mapped 10 AI predictions based on industry trends and what we're hearing from founders and operators on the front lines. Here’s what we see shaping 2026.

What will define AI in 2026? 10 predictions on enterprise, infrastructure, and what’s coming next.

The AI bubble debate continues, but demand keeps rising. Here are 10 predictions we believe will shape AI and enterprise in 2026.

When Stanford-trained physician Michelle Longmire M.D. saw an opportunity to tackle one of the toughest challenges in healthcare: the slow, manual, and resource-constrained process of running clinical trials, she set out to build Medable, Inc. 🧬🔬 Fast forward to today, Medable is helping transform how medicines are developed by applying agentic AI to remove bottlenecks, accelerate research, and expand access to life-changing therapies. In our latest episode of Five with Founders, Cathy Gao sits down with Founder and CEO Michelle Longmire to explore: -How Medable has navigated multiple market cycles by staying anchored to its mission -How agentic AI is unlocking one of the biggest constraints in drug development -What the future of clinical trials looks like as automation moves from concept to reality -The characteristics of investors who truly add value in life sciences and technology Check out their full conversation below. ⬇️